Dual Immune Checkpoint Blockade and Hypofractionated Radiation in Patients With Salivary Gland Cancers
Phase of Trial: Phase I/II
Latest Information Update: 08 Mar 2019
Price : $35 *
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Salivary gland cancer
- Focus Adverse reactions
- 07 Feb 2019 Status changed from not yet recruiting to recruiting.
- 07 Jan 2019 Planned initiation date changed from 22 Dec 2018 to 22 Jan 2019.
- 28 Nov 2018 New trial record